Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Amgen will pay Advaxis $40 million up front and buy $25 million in Advaxis stock for rights to the personalized cancer immunotherapy ADXS-NEO. The treatment is created by sequencing a patient’s healthy and cancer cells to identify neoepitopes, or markers on antigens, that are most likely to prompt an immune response. Advaxis then uses an engineered strain of bacteria to deliver neoepitope peptides directly into cells that tell the immune system to recognize and combat tumor cells. The companies expect to start the first clinical trials of ADXS-NEO next year.
This article has been sent to the following recipient: